Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

ACRS Aclaris Therapeutics, Inc.
$6.54 3.57% +0.22
Notify me if price changes either direction
Interactive Brokers Logotype

Buy ACRS stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 961.9M
Enterprise value 853.8M
Trailing PE -12.339622569534
Forward PE -7.8940887
PEG Ratio -0.80207546701971
Enterprise to EBITDA -9.984
Enterprise to revenue 103.886
Price to book MRQ 7.194164
Price to sales TTM 114.80045

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 8.2M
EBITDA -85525000
Diluted EPS TTM -0.58
Total Cash (MRQ) 91.6M
Current ratio (MRQ) 3.462
Operating Cash Flow (TTM) -62059000

ACRS trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent ACRS News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.